MYH6

From WikiMD's WELLNESSPEDIA

MYCN
Symbol MYCN
HGNC ID 7608
Alternative symbols
Entrez Gene 4613
OMIM 164840
RefSeq NM_005378
UniProt P04198
Chromosome 2p24.3
Locus supplementary data


MYCN (v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog) is a gene that encodes a protein known as N-Myc, which is a member of the Myc family of transcription factors. This gene is located on the short arm of chromosome 2 (2p24.3) and plays a crucial role in cell cycle regulation, apoptosis, and cellular differentiation.

Function[edit]

The MYCN gene is primarily expressed during embryogenesis and is involved in the regulation of neurodevelopment. The N-Myc protein functions as a transcription factor that binds to specific DNA sequences, thereby regulating the expression of target genes involved in cell proliferation and growth. It is particularly important in the development of the nervous system, where it helps to control the balance between cell proliferation and differentiation.

Clinical Significance[edit]

MYCN amplification is a well-known marker of poor prognosis in neuroblastoma, a type of cancer that arises from neural crest cells and primarily affects children. Amplification of the MYCN gene leads to overexpression of the N-Myc protein, which drives uncontrolled cell proliferation and tumorigenesis. This genetic alteration is found in approximately 20-25% of neuroblastoma cases and is associated with rapid disease progression and resistance to therapy.

In addition to neuroblastoma, MYCN amplification has been observed in other types of cancer, including medulloblastoma, retinoblastoma, and certain gliomas. The role of MYCN in these cancers is an active area of research, with efforts focused on developing targeted therapies that can inhibit N-Myc function.

Research and Therapeutic Approaches[edit]

Given the critical role of MYCN in cancer, there is significant interest in developing therapeutic strategies to target N-Myc. Approaches include:

  • Small molecule inhibitors: Compounds that directly inhibit the function of N-Myc or its interaction with other proteins.
  • RNA interference (RNAi): Techniques to reduce MYCN expression at the mRNA level.
  • Immunotherapy: Strategies to target MYCN-expressing cells using the immune system.

Also see[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.